Leerink Partnrs Has Bullish Outlook for KROS FY2026 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Investment analysts at Leerink Partnrs upped their FY2026 earnings estimates for Keros Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($4.66) per share for the year, up from their previous forecast of ($4.86). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics’ FY2027 earnings at ($4.16) EPS, FY2028 earnings at ($1.95) EPS and FY2029 earnings at ($2.60) EPS.

Several other analysts also recently issued reports on KROS. Oppenheimer reduced their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, January 16th. Guggenheim reiterated a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Cantor Fitzgerald downgraded Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Finally, HC Wainwright decreased their price objective on Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $42.33.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $11.10 on Monday. The stock has a market capitalization of $449.63 million, a PE ratio of -2.13 and a beta of 1.39. Keros Therapeutics has a 52 week low of $9.77 and a 52 week high of $72.37. The stock has a 50 day moving average price of $12.40 and a two-hundred day moving average price of $39.25.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million.

Institutional Trading of Keros Therapeutics

A number of hedge funds have recently bought and sold shares of KROS. KBC Group NV raised its stake in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares during the last quarter. AlphaQuest LLC raised its position in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after acquiring an additional 2,964 shares during the period. LMR Partners LLP purchased a new position in Keros Therapeutics in the third quarter valued at about $213,000. Finally, Victory Capital Management Inc. purchased a new position in Keros Therapeutics in the third quarter valued at about $216,000. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.